Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | RAB9A | P51151 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.64 |
| ▸ | CASP3 | P42574 | 1/20 | 0.64 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.64 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.64 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | LTA4H | P09960 | 4/20 | 0.55 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3645648 | 1.00 | ALDH1A1 (0.66) | ALDH1A1RAB9ANPC1GPR55CASP3 | |
| SCHEMBL5040554 | 0.87 | MEN1 (0.55) | ALDH1A1RAB9ANPC1GPR55CASP3 | |
| SCHEMBL5040549 | 0.87 | MEN1 (0.55) | ALDH1A1RAB9ANPC1GPR55CASP3 | |
| SCHEMBL3693754 | 0.85 | ALDH1A1 (0.49) | ALDH1A1RAB9ANPC1GPR55CASP3 | |
| SCHEMBL3693757 | 0.85 | ALDH1A1 (0.49) | ALDH1A1RAB9ANPC1GPR55CASP3 | |
| SCHEMBL11715321 | 0.85 | ALDH1A1 (0.68) | ALDH1A1RAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL11715338 | 0.85 | ALDH1A1 (0.68) | ALDH1A1RAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL1974848 | 0.84 | MAPT (0.51) | ALDH1A1RAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL1717228 | 0.84 | MAPT (0.51) | ALDH1A1RAB9ANPC1SMN1; SMN2MAPT | |
| SCHEMBL1717226 | 0.84 | MAPT (0.51) | ALDH1A1RAB9ANPC1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2182950-B1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LTD (GB) | 2017-07-19 | — | — | EP | disclosed |
| US-8759348-B2 | Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms | HELPERBY THERAPEUTICS LIMITED (GB) | 2014-06-24 | — | — | US | disclosed |
| US-20100305065-A1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2010-12-02 | — | — | US | disclosed |
| EP-2182950-A1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | Helperby Therapeutics Limited (GB) | 2010-05-12 | — | — | EP | disclosed |
| WO-2008142384-A1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008117079-A1 | ANTIMICROBIAL COMPOUNDS BASED UPON 4-AMINOQUINOLINE | HELPERBY THERAPEUTICS LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305065-A1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | ARG1, LPO, CTSL | ALDH1A1 377/4885RAB9A 1593/4885NPC1 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.